Intelligent Bio Solutions Inc. (INBS) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Intelligent Bio Solutions Inc. (NASDAQ: INBS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $1.83 (+9.58% 1D, market cap $6.1M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, INBS ranks #732 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), INBS carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 40.8%, and ROIC of -35.0%. By comparison, TNON (Tenon Medical Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $6.2M) and SNOA (Sonoma Pharmaceuticals Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $5.7M). Among the 5-stock peer group, INBS leads on earnings multiple (N/A) while INBS leads on capital efficiency (-35.0% ROIC).
Per INBS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001725430), Intelligent Bio Solutions Inc. generated $3.1M in revenue (-1.9% YoY), -$10.6M in net income, and -$9.9M in free cash flow against $17.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 53.2 (NEUTRAL RANGE)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While INBS currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.88) and Max Pain ($1.92) forces dealer call-delta covering toward $26.14.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Intelligent Bio Solutions Inc. (INBS) surged +9.58% to $1.83, trading at 2% of its 52-week range ($1.35 – $24.9). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Gainers SCWorx (NASDAQ:WORX) stock rose 47.8% to $3.96 during Tuesday's pre-market session. Integra Lifesciences (NASDAQ:IART) shares increased by 31.97% to $17.75. The market value of their outstanding shares is
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -1.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on INBS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for INBS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Intelligent Bio Solutions Inc. (INBS) ranks #732 by composite RQD confidence (38/100, grade D-) and #928 by equity capitalization ($6.1M). Within this direct 5-issuer industry benchmark cohort, INBS leads on earnings valuation at N/A trailing P/E, while INBS leads on capital efficiency and profitability with -35.0% ROIC and 40.8% gross margin. WOK currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with INBS at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| INBS
ACTIVE
Intelligent Bio Solutions Inc. | D- | 38/100 | — | 40.8% | -35.0% | +9.58% | $6.1M | Benchmark Subject |
| TNON Tenon Medical Inc. | D- | 43/100 | — | 59.8% | -35.0% | +1.33% | $6.2M | /tnon-vs-inbs → |
| SNOA Sonoma Pharmaceuticals Inc. | D | 44/100 | — | 38.0% | -35.0% | +5.26% | $5.7M | /snoa-vs-inbs → |
| WOK WORK Medical Technology Group LTD (Class A) | D+ | 54/100 | — | — | — | -4.35% | $4.9M | /wok-vs-inbs → |
| NVNO enVVeno Medical Corporation | D | 50/100 | — | — | -35.0% | +4.08% | $4.9M | /nvno-vs-inbs → |
In its most recent audited fiscal period (FY2025, filed 2025-06-30), Intelligent Bio Solutions Inc. (INBS) reported GAAP revenue of $3.1M (-1.9% vs. FY2024 revenue of $3.1M , and +142.9% cumulative change since FY2023) , GAAP net income of -$10.6M, operating cash flow of -$9.7M, and free cash flow of -$9.9M (-1.2% YoY). On the balance sheet, INBS closed FY2025 with $17.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $3.1M | -$10.6M | -$9.7M | -$9.9M | $17.7M | — |
| FY2024 (FY) | 2024-06-30 | $3.1M | -$10.2M | -$9.6M | -$9.8M | $8.7M | — |
| FY2023 (FY) | 2023-06-30 | $1.3M | -$10.6M | -$7.4M | -$7.4M | — | — |
As of 2026-11-01, Intelligent Bio Solutions Inc. (NASDAQ: INBS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $1.83 (+9.58% 1D, market cap $6.1M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, INBS ranks #732 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), INBS carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 40.8%, and ROIC of -35.0%. By comparison, TNON (Tenon Medical Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $6.2M) and SNOA (Sonoma Pharmaceuticals Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $5.7M). Among the 5-stock peer group, INBS leads on earnings multiple (N/A) while INBS leads on capital efficiency (-35.0% ROIC).
Per INBS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001725430), Intelligent Bio Solutions Inc. generated $3.1M in revenue (-1.9% YoY), -$10.6M in net income, and -$9.9M in free cash flow against $17.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
INBS last traded at $1.83 (+9.58% on volume of 30,886 shares), positioning the stock -2.66% below its 50-day simple moving average ($1.88) and -42.27% below its 200-day simple moving average ($3.17). Across its 52-week range of $1.35 to $24.90, INBS sits at the 2.0% percentile with a 14-day RSI of 53.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.60 to $2.06).
Why INBS Stock surged +9.58% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).